Q-omics provides the consensus-scored THEM5 profile across patient tissues and cancer cell-line models. THEM5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, THEM5 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, THEM5 RNA expression shows 17,114 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, LIHC, and UVM as cancer lineages where THEM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THEM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THEM5 survival associations across molecular data types. THEM5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THEM5 RNA expression–survival associations across cancer types. High THEM5 expression shows unfavorable associations in LGG, KIRP and UVM, but favorable associations in SCLC, SKCM and ACC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify SCLC as the clearest survival context for THEM5 RNA expression.
This table summarizes THEM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for THEM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THEM5 shows lower tumor expression in BRCA and KICH and higher tumor expression in LIHC, LUAD, LUSC and CHOL. The LIHC box plot shows higher THEM5 RNA expression in tumor versus normal tissue (log2 FC = +2.393, t-test p < 0.001).
This table shows molecular features associated with THEM5 in patient tissues and cancer cell lines. In patient samples, THEM5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, THEM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
